JPWO2021030657A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021030657A5
JPWO2021030657A5 JP2022507875A JP2022507875A JPWO2021030657A5 JP WO2021030657 A5 JPWO2021030657 A5 JP WO2021030657A5 JP 2022507875 A JP2022507875 A JP 2022507875A JP 2022507875 A JP2022507875 A JP 2022507875A JP WO2021030657 A5 JPWO2021030657 A5 JP WO2021030657A5
Authority
JP
Japan
Prior art keywords
cys
scfv
seq
exposed
disulfide bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022507875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544760A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046303 external-priority patent/WO2021030657A1/en
Publication of JP2022544760A publication Critical patent/JP2022544760A/ja
Publication of JPWO2021030657A5 publication Critical patent/JPWO2021030657A5/ja
Pending legal-status Critical Current

Links

JP2022507875A 2019-08-15 2020-08-14 改善された単鎖可変断片のための材料及び方法 Pending JP2022544760A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201962887524P 2019-08-15 2019-08-15
US201962887514P 2019-08-15 2019-08-15
US201962887529P 2019-08-15 2019-08-15
US201962887519P 2019-08-15 2019-08-15
US201962887527P 2019-08-15 2019-08-15
US62/887,519 2019-08-15
US62/887,514 2019-08-15
US62/887,529 2019-08-15
US62/887,527 2019-08-15
US62/887,524 2019-08-15
US201962946877P 2019-12-11 2019-12-11
US201962946882P 2019-12-11 2019-12-11
US201962946897P 2019-12-11 2019-12-11
US201962946886P 2019-12-11 2019-12-11
US201962946865P 2019-12-11 2019-12-11
US62/946,877 2019-12-11
US62/946,865 2019-12-11
US62/946,897 2019-12-11
US62/946,886 2019-12-11
US62/946,882 2019-12-11
PCT/US2020/046303 WO2021030657A1 (en) 2019-08-15 2020-08-14 Materials and methods for improved single chain variable fragments

Publications (2)

Publication Number Publication Date
JP2022544760A JP2022544760A (ja) 2022-10-21
JPWO2021030657A5 true JPWO2021030657A5 (zh) 2023-08-15

Family

ID=72243247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507875A Pending JP2022544760A (ja) 2019-08-15 2020-08-14 改善された単鎖可変断片のための材料及び方法

Country Status (18)

Country Link
US (2) US11787875B2 (zh)
EP (1) EP4013783A1 (zh)
JP (1) JP2022544760A (zh)
KR (1) KR20220062494A (zh)
CN (1) CN114258400A (zh)
AU (1) AU2020328049A1 (zh)
BR (1) BR112022002540A2 (zh)
CA (1) CA3148121A1 (zh)
CO (1) CO2022001222A2 (zh)
CR (1) CR20220054A (zh)
DO (1) DOP2022000032A (zh)
EC (1) ECSP22011199A (zh)
IL (1) IL290436A (zh)
JO (1) JOP20220035A1 (zh)
MX (1) MX2022001799A (zh)
PE (1) PE20220299A1 (zh)
TW (1) TW202120537A (zh)
WO (1) WO2021030657A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506750A (ja) * 2019-12-11 2023-02-20 シラグ・ゲーエムベーハー・インターナショナル Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用
WO2023089587A1 (en) * 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
WO2023164510A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-cd28 x anti-psma antibodies
WO2024028731A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
MX2009010639A (es) 2007-04-02 2009-10-23 Philogen Spa Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102089431A (zh) * 2008-06-30 2011-06-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 官能化的多肽
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CA2769619C (en) 2009-08-17 2019-04-30 Roche Glycart Ag Targeted immunoconjugates
ES2667258T3 (es) * 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
AU2010336029B2 (en) * 2009-12-23 2011-10-13 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
CN103068846B9 (zh) * 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
TWI588156B (zh) * 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
CN104080811B (zh) 2011-11-04 2019-09-27 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
DK2794905T3 (da) 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
WO2013175678A1 (ja) * 2012-05-24 2013-11-28 パナソニック株式会社 ヒト心筋由来トロポニンｉに特異的にかつ速やかに結合できる変異体タンパク質
SG11201507577RA (en) 2013-03-15 2015-10-29 Janssen Biotech Inc Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
EP3684816B1 (en) 2017-09-22 2024-05-29 Kite Pharma, Inc. Chimeric polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
CN111246885B (zh) 从单特异性抗体生成多特异性抗体的方法
US20190263909A1 (en) Bispecific and monospecific antibodies using novel anti-pd-1 sequences
JP2020522266A5 (zh)
JP6742245B2 (ja) 多重特異性抗体
EP2435473B1 (en) Tri- or tetraspecific antibodies
RU2018108103A (ru) КОНСТРУКЦИИ, ИМЕЮЩИЕ SIRP-α ДОМЕН ИЛИ ЕГО ВАРИАНТ
RU2019108429A (ru) Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
CA2917886A1 (en) Bispecific cd3 and cd19 antigen binding constructs
RU2015101699A (ru) Слитые полипептиды и конъюгаты полипептида лиганда рецептора инкретина и fc-области с измененной fc-эффекторной функцией
US20200140568A1 (en) Biparatopic and multiparatopic antibodies with common light chain and method of use
CA2876099A1 (en) Method for producing monomeric and multimeric molecules and uses thereof
US20220119549A1 (en) Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
CA3078676A1 (en) Method for in vivo generation of multispecific antibodies from monospecific antibodies
JPWO2021030657A5 (zh)
Mimoto et al. Fc engineering to improve the function of therapeutic antibodies
CA3133898A1 (en) Activatable therapeutic multispecific polypeptides with extended half-life
JPWO2021019389A5 (zh)
CA3203831A1 (en) Bi- or multi-specific antibody
JPWO2019140273A5 (zh)
RU2021121021A (ru) Способы получения гетеродимерных антител
JPWO2020128870A5 (zh)
JPWO2021240388A5 (zh)
TW202233663A (zh) 多特異性抗原結合結構域之新穎的連接子
JPWO2021030488A5 (zh)